Invasive lobular carcinoma (ILC) of the breast, characterized by loss of E-cadherin expression, accounts for 5-15% of invasive breast cancers and it is believed to arise via a linear histological progression. Genomic studies have identified a clonal relationship between ILC and concurrent lobular carcinoma in situ (LCIS) lesions, suggesting that LCIS may be a precursor lesion. It has been shown...

BACKGROUND Invasive pleomorphic lobular carcinoma (PLC) is an aggressive subtype of invasive lobular carcinoma of the breast, which has its own histopathological and biological features. The metastatic patterns for PLC are distinct from those of invasive ductal carcinoma. In addition, pancreatic metastasis from PLC is extremely rare. CASE PRESENTATION We report a rare case of a 48-year-old wo...

There is currently much speculation over the precise nature of lobular carcinoma in-situ of the breast and its significance. Histochemical study shows that it is rich in sialomucin. This has a characteristic intracellular distribution which distinghishes lobular carcinoma in-situ from cancerization of lobules. The same histochemical features are seen in the infiltrative phase of the tumour. The...

After invasive ductal carcinoma, lobular carcinoma (ILC) is the most frequent breast cancer and accounts for nearly 15% of all cancers (BC). Doxorubicin (DXR) a very effective chemotherapeutic drug utilized to treat BC but induces resistance severe side effects. Recently, liposomes have gained popularity as tumor microenvironment (TME) modulatory anticancer agents various malignancies, includin...

The present study aimed to investigate the possibility of using dual-energy computed tomography (CT) before therapy to discriminate between normal breast tissue and tumor tissue in patients with breast cancer, without the need to use a contrast medium. The following patient data were extracted by interview and from the hospital’s radiology information system: height, weight, age, menstrual cycl...

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S1 Section 1 Multidisciplinary care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...